<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133350</url>
  </required_header>
  <id_info>
    <org_study_id>19P.115</org_study_id>
    <nct_id>NCT04133350</nct_id>
  </id_info>
  <brief_title>Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy Pilot Registry (PEP ASV Pilot Registry)</brief_title>
  <acronym>PEP-ASV</acronym>
  <official_title>Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy Pilot Registry (PEP ASV Pilot Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inova Fairfax Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CLEMENS HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Resmed Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, unblinded pilot study and registry that aims to
      demonstrate adherence to adaptive servo-ventilation (ASV) therapy in patients with moderate
      to severe sleep disordered breathing who have been recently hospitalized. ASV therapy has
      been linked to improved outcomes in this population, but adherence to therapy is low. The
      AirCurve 10 ASV device that will be used for this study employs newer technologies, such as
      web-based monitoring and provides patients feedback, which may increase therapy adherence and
      therefore improve patient outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 16, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence (hours/night)</measure>
    <time_frame>3 months</time_frame>
    <description>Demonstrate acceptable adherence to ASV therapy can be achieved in patients with moderate to severe SDB in a recently hospitalized population of Heart Failure patients with preserved ejection fraction (HFpEF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>3 months</time_frame>
    <description>The study will determine if acceptable adherence to this therapy can be achieved in this population using the AirCurve 10 device.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sleep Disorder; Breathing-Related</condition>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Patient Engagement</intervention_name>
    <description>The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients 18 years or older 2. Patients with heart failure with preserved ejection
             fraction (HFpEF; LVEF ≥50%) 3. Hospital admission or equivalent (such as ER visit
             alone or clinic visit alone) and acute decompensated HF as determined by:

               1. Dyspnea at rest or with minimal exertion AND

               2. Treatment with at least one dose of IV diuretic or ultrafiltration AND

               3. At least two of the following signs and symptoms:

             i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest
             X-ray iv. Local BNP or NT pro-BNP level:

          -  No current AFib: BNP≥100 pg/mL or NT pro-BNP≥300 pg/mL OR

          -  Current AFib: BNP≥150 pg/mL or NT pro-BNP≥450 pg/mL 4. Sleep disordered breathing
             (SDB) documented by screening polygraphy with an AHI≥15 events/hour (e/hr) 5. Patient
             is able to fully understand study information and sign informed consent

        Exclusion Criteria:

          1. Right-sided heart failure without left-sided failure

          2. Current chronic use (within 4 weeks of registry entry) of any PAP therapy (e.g., CPAP,
             APAP, or bi-level) or contraindicated for PAP therapy

          3. Sustained systolic blood pressure &lt;80 mmHg at baseline

          4. Complex congenital heart disease

          5. Constrictive pericarditis

          6. Chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the
             day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day
             or night)

          7. Transient ischemic attack (TIA) or Stroke within 3 months prior to registry entry

          8. Definite clinically evident acute myocardial infarction within 3 months of registry
             entry

          9. Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas

         10. Moderate or greater valvular heart disease as the primary reason for heart failure

         11. In the opinion of the investigator, the index acute decompensated HF event was not due
             primarily to uncontrolled AFib with fast ventricular response rate

         12. Inability to comply with planned study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire Chenault, MS</last_name>
    <phone>2159557835</phone>
    <email>mcc035@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Chenault</last_name>
      <phone>215-955-7835</phone>
      <email>mcc035@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>David Whellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA (Inova Heart and Vascular Institute, Inova Fairfax Hospital)</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Garofalo</last_name>
      <phone>703-776-2018</phone>
      <email>stephanie.garofalo@inova.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Psotka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum, Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Ruhr-Universität Bochum</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Fox</last_name>
      <email>hfox@hdz.nrw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludgerus Clinic, Department of Cardiology, Clemens Hospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Oldenburg</last_name>
      <phone>49 251-976-2481</phone>
      <email>o.oldenburg@alexianer.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>David Whellan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

